ROCKVILLE, Md., April 30, 2019 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE American: SYN), a late-stage clinical company
developing therapeutics that preserve the microbiome to protect and
restore the health of patients, announced today that the Company
intends to release its operational highlights and financial results
for the quarter ended March 31, 2019
on Wednesday, May 8, 2019, and to
host a conference call the same day at 4:30
p.m. ET. The dial-in information for the call is as
follows:
U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280
Participants are asked to dial in 15 minutes before the
start of the call to register. The call will also be webcast over
the Internet
at https://www.webcaster4.com/Webcast/Page/1096/30393. An
archived replay of the call will be available for approximately
ninety (90) days at the same
URL, https://www.webcaster4.com/Webcast/Page/1096/30393 beginning
approximately one hour after the call's conclusion.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a
clinical-stage company developing therapeutics that preserve the
microbiome to protect and restore the health of patients. The
Company's lead candidates are: (1) SYN-004 (ribaxamase) which is
designed to degrade certain commonly used intravenous (IV)
beta-lactam antibiotics within the gastrointestinal (GI) tract to
prevent microbiome damage, C. difficile infection (CDI),
overgrowth of pathogenic organisms, the emergence of antimicrobial
resistance (AMR) and acute graft-versus-host-disease (aGVHD) in
allogeneic hematopoietic cell transplant (HCT) recipients, and (2)
SYN-010, which is intended to reduce the impact of
methane-producing organisms in the gut microbiome to treat an
underlying cause of irritable bowel syndrome with constipation
(IBS-C). The Company's preclinical pursuits include SYN-020, an
oral formulation of the enzyme intestinal alkaline phosphatase
(IAP) to treat both local GI and systemic diseases as well as
monoclonal antibody therapies for the prevention and treatment of
pertussis. For more information, please visit Synthetic Biologics'
website at www.syntheticbiologics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2019-first-quarter-operational-highlights-and-financial-results-on-may-8-2019-300841094.html
SOURCE Synthetic Biologics, Inc.